serological profile of patients with systemic sclerosis

Clicks: 348
ID: 164191
2014
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #6 of 41 articles by views in voprosy pitaniia

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Introduction: The systemic sclerosis–associated autoantibodies include anti-centromere, anti-topoisomerase I (anti-topo I), anti-RNA polymerase III, anti-fibrillarin, anti-Th/To, and anti-PDGFR. A specific serological profile is connected with clinical manifestations and prognosis in systemic sclerosis (SSc).Objectives: The aim of the study was to assess the serological profile in limited cutaneous and diffuse cutaneous SSc (lcSSc and dcSSc).Patients and methods: 87 (68 female and 19 male) consecutive SSc patients treated between 2006 and 2011 were assessed. Patients fulfilled the American College of Rheumatology classification criteria of SSc: 35 – dcSSc and 52 – lcSSc. The following marker antibodies were determined: anti-topo I, anti-centromere A and B (CENP A, CENP B), anti-RNA polymerase III (RP11, RP 155), anti-fibrillarin (U3RNP), anti- -NOR90, anti-Th/To, anti-PM-Scl-100, anti-PM-Scl-75, anti-Ku, anti-Ro-52, anti-PDGFR. The presence of antibodies was assessed using a test – EUROLINE Systemic Sclerosis Profile.Results: 82 patients (94%) had positive antinuclear antibodies; anti-topo I – 29 patients; anti-CENP-A – 20 and anti-CENP-B – 20; anti-RP11 – 9 and anti-RP155 – 7; anti-U3RNP – 1; anti-NOR90 – 6; anti-Th/ To – 3; anti-PM-Scl-100 – 7; anti-PM-Scl-75 – 11; anti-Ku – 5; anti-Ro-52 – 23 patients. We found significant differences in prevalence of anti-topo I: 25/35 vs. 4/52 p=0.0000; anti-CENP A: 0/35 vs. 20/52 p=0.0001; anti-CENP B: 0/35 vs. 20/52 p=0.0001 between dcSSc and lcSSc.Conclusions: Some antibodies in SSc, e.g. anti-topo I and anti-centromere, are useful in defining the clinical subset of disease and provide prognostic information. There are no significant differences in the prevalence of other autoantibodies associated with SSc between dcSSc and lcSSc patients.
Reference Key
wielosz2014postpyserological Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors ;Ewa Wielosz;Magdalena Dryglewska;Maria Majdan
Journal voprosy pitaniia
Year 2014
DOI
10.5604/01.3001.0003.1271
URL
http://phmd.pl/gicid/pdf/01.3001.0003.1271
Keywords
autoantibodies systemic sclerosis

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.